Company registration number 00920009 (England and Wales)
CONTACT LENS PRECISION LABORATORIES LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
CONTACT LENS PRECISION LABORATORIES LIMITED
COMPANY INFORMATION
Directors
S Cross
N Shinjo
T Sugiyama
T Sato
(Appointed 24 July 2025)
T Kinoshita
(Appointed 18 March 2026)
Secretary
S Cross
Company number
00920009
Registered office
Dolphin House
Commerce Way
Leighton Buzzard
Bedfordshire
LU7 4RW
Auditor
Mercer & Hole LLP
The Pinnacle
170 Midsummer Boulevard
Milton Keynes
Buckinghamshire
MK9 1BP
CONTACT LENS PRECISION LABORATORIES LIMITED
CONTENTS
Page
Directors' report
1
Directors' responsibilities statement
2
Independent auditor's report
3 - 5
Group statement of comprehensive income
6
Group balance sheet
7
Company balance sheet
8
Group statement of changes in equity
9
Company statement of changes in equity
10
Group statement of cash flows
11
Notes to the financial statements
12 - 28
CONTACT LENS PRECISION LABORATORIES LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 1 -

The directors present their annual report and financial statements for the year ended 31 December 2025.

Principal activities

The principal activity of the company and group during the year continued to be that of the development, manufacture and sale of specialist contact lenses.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

S Cross
N Shinjo
T Sugiyama
M Urakabe
(Resigned 24 June 2025)
S Kubota
(Resigned 18 March 2026)
M Kumasaka
(Resigned 24 June 2025)
T Sato
(Appointed 24 July 2025)
T Kinoshita
(Appointed 18 March 2026)
Auditor

The auditor, Mercer & Hole LLP, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

This report has been prepared in accordance with the provisions applicable to groups and companies entitled to the exemptions of the small companies regime.

On behalf of the board
S Cross
Director
27 May 2026
CONTACT LENS PRECISION LABORATORIES LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

United Kingdom company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the group and parent company financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and parent company, and of the profit or loss of the group for that period.

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and parent company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and parent company, and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and parent company, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

CONTACT LENS PRECISION LABORATORIES LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF CONTACT LENS PRECISION LABORATORIES LIMITED
- 3 -
Opinion

We have audited the financial statements of Contact Lens Precision Laboratories Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2025 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

CONTACT LENS PRECISION LABORATORIES LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF CONTACT LENS PRECISION LABORATORIES LIMITED
- 4 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

 

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the group's and parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or parent company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

We gained an understanding of the legal and regulatory framework applicable to the group and the industry in which it operates and considered the risk of acts by the group that were contrary to applicable laws and regulations, including fraud. These included, but were not limited to, the Companies Act 2006 and tax legislation.

We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements and the financial report (including the risk of override of controls), and determined that the principal risks were related to posting inappropriate entries including journals to overstate revenue or understate expenditure and management bias in accounting estimates.

Audit procedures performed by the engagement team included:

CONTACT LENS PRECISION LABORATORIES LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF CONTACT LENS PRECISION LABORATORIES LIMITED
- 5 -

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non- compliance and cannot be expected to detect non-compliance with all laws and regulations.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the parent company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the parent company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the parent company and the parent company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Andrew Lawes MA MSc FCA (Senior Statutory Auditor)
For and on behalf of Mercer & Hole LLP
27 May 2026
Chartered Accountants
Statutory Auditor
The Pinnacle
170 Midsummer Boulevard
Milton Keynes
Buckinghamshire
MK9 1BP
CONTACT LENS PRECISION LABORATORIES LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2025
- 6 -
2025
2024
Notes
£
£
Turnover
3
3,812,892
3,135,809
Cost of sales
(1,609,345)
(1,031,377)
Gross profit
2,203,547
2,104,432
Distribution costs
(655,361)
(684,062)
Administrative expenses
(2,378,021)
(1,606,278)
Other operating income
144,307
236,105
Operating (loss)/profit
4
(685,528)
50,197
Interest receivable and similar income
8
153
-
0
(Loss)/profit before taxation
(685,375)
50,197
Tax on (loss)/profit
9
102,903
(85,888)
Loss for the financial year
21
(582,472)
(35,691)
Loss for the financial year is all attributable to the owners of the parent company.
CONTACT LENS PRECISION LABORATORIES LIMITED
GROUP BALANCE SHEET
AS AT 31 DECEMBER 2025
31 December 2025
- 7 -
2025
2024
Notes
£
£
£
£
Fixed assets
Goodwill
10
2,236,489
-
0
Other intangible assets
10
141,706
80,392
Total intangible assets
2,378,195
80,392
Tangible assets
11
2,138,473
2,146,124
4,516,668
2,226,516
Current assets
Stocks
14
398,833
549,164
Debtors
15
1,037,481
1,123,423
Cash at bank and in hand
734,115
924,050
2,170,429
2,596,637
Creditors: amounts falling due within one year
16
(352,554)
(334,031)
Net current assets
1,817,875
2,262,606
Total assets less current liabilities
6,334,543
4,489,122
Creditors: amounts falling due after more than one year
17
(3,488)
-
Provisions for liabilities
Deferred tax liability
18
44,504
20,099
(44,504)
(20,099)
Net assets
6,286,551
4,469,023
Capital and reserves
Called up share capital
20
111
111
Share premium account
21
17,982
17,982
Revaluation reserve
21
251,383
260,166
Capital redemption reserve
21
16
16
Capital contribution reserve
21
2,400,000
-
0
Profit and loss reserves
21
3,617,059
4,190,748
Total equity
6,286,551
4,469,023
The financial statements were approved by the board of directors and authorised for issue on 27 May 2026 and are signed on its behalf by:
27 May 2026
S Cross
Director
Company registration number 00920009 (England and Wales)
CONTACT LENS PRECISION LABORATORIES LIMITED
COMPANY BALANCE SHEET
AS AT 31 DECEMBER 2025
31 December 2025
- 8 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
10
141,706
80,392
Tangible assets
11
615,922
635,322
Investments
12
3,889,204
50
4,646,832
715,764
Current assets
Debtors
15
309,663
2,824,874
Cash at bank and in hand
490,470
572,143
800,133
3,397,017
Creditors: amounts falling due within one year
16
(1,435,567)
(168,247)
Net current (liabilities)/assets
(635,434)
3,228,770
Total assets less current liabilities
4,011,398
3,944,534
Provisions for liabilities
18
(35,428)
(20,099)
Net assets
3,975,970
3,924,435
Capital and reserves
Called up share capital
20
111
111
Share premium account
21
17,982
17,982
Revaluation reserve
21
237,635
244,891
Capital redemption reserve
21
16
16
Capital contribution reserve
21
2,400,000
-
0
Profit and loss reserves
21
1,320,226
3,661,435
Total equity
3,975,970
3,924,435

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s loss for the year was £2,348,465 (2024: £239,928 profit).

The financial statements were approved by the board of directors and authorised for issue on 27 May 2026 and are signed on its behalf by:
27 May 2026
S Cross
Director
Company Registration No. 00920009
CONTACT LENS PRECISION LABORATORIES LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 9 -
Share capital
Share premium account
Revaluation reserve
Capital redemption reserve
Capital contribution reserve
Profit and loss reserves
Total
£
£
£
£
£
£
£
Balance at 1 January 2024
111
17,982
269,119
16
-
4,217,486
4,504,714
Year ended 31 December 2024:
Loss and total comprehensive income
-
-
-
-
-
(35,691)
(35,691)
Transfers
-
-
(8,953)
-
-
8,953
-
Balance at 31 December 2024
111
17,982
260,166
16
-
4,190,748
4,469,023
Year ended 31 December 2025:
Loss and total comprehensive income
-
-
-
-
-
(582,472)
(582,472)
Transfers
-
-
(8,783)
-
-
8,783
-
Capital contribution
-
-
-
-
2,400,000
-
2,400,000
Balance at 31 December 2025
111
17,982
251,383
16
2,400,000
3,617,059
6,286,551
CONTACT LENS PRECISION LABORATORIES LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
Share capital
Share premium account
Revaluation reserve
Capital redemption reserve
Capital contribution reserve
Profit and loss reserves
Total
£
£
£
£
£
£
£
Balance at 1 January 2024
111
17,982
252,147
16
-
3,414,251
3,684,507
Year ended 31 December 2024:
Profit and total comprehensive income for the year
-
-
-
-
-
239,928
239,928
Transfers
-
-
(7,256)
-
-
7,256
-
Balance at 31 December 2024
111
17,982
244,891
16
-
3,661,435
3,924,435
Year ended 31 December 2025:
Profit and total comprehensive income
-
-
-
-
-
(2,348,465)
(2,348,465)
Transfers
-
-
(7,256)
-
-
7,256
-
Capital contribution
-
-
-
-
2,400,000
-
2,400,000
Balance at 31 December 2025
111
17,982
237,635
16
2,400,000
1,320,226
3,975,970
CONTACT LENS PRECISION LABORATORIES LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 11 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash absorbed by operations
25
(546,717)
(106,839)
Income taxes (paid)/refunded
(34,442)
15,915
Net cash outflow from operating activities
(581,159)
(90,924)
Investing activities
Purchase of business net of cash acquired
(1,896,695)
-
Purchase of intangible assets
(61,314)
(81,068)
Purchase of tangible fixed assets
(50,920)
(420,553)
Interest received
153
-
0
Net cash used in investing activities
(2,008,776)
(501,621)
Financing activities
Capital contributions received
2,400,000
-
Net cash generated from/(used in) financing activities
2,400,000
-
Net decrease in cash and cash equivalents
(189,935)
(592,545)
Cash and cash equivalents at beginning of year
924,050
1,516,595
Cash and cash equivalents at end of year
734,115
924,050
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 12 -
1
Accounting policies
Company information

Contact Lens Precision Laboratories Limited (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is Dolphin House, Commerce Way, Leighton Buzzard, Bedfordshire, LU7 4RW.

 

The group consists of Contact Lens Precision Laboratories Limited and all of its subsidiaries.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention modified to include the revaluation of freehold properties and certain plant and equipment. The principal accounting policies adopted are set out below.

The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:

 

The consolidated group financial statements consist of the financial statements of the parent company Contact Lens Precision Laboratories Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.

 

All financial statements are made up to 31 December 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

1.2
Going concern

The financial statements have been prepared on a going concern basis.  In making this assessment, the directors have prepared detailed trading and cash flow forecasts to June 2027 and have obtained a signed letter of support from the ultimate controlling company. On this basis, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence over this period and have therefore adopted the going concern basis of accounting in preparing the financial statements.

CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 13 -
1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from royalties is recognised as they are earned.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.5
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

1.6
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs
10% straight line
1.7
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold land and buildings
1%-2% straight line
Plant and machinery
10% & 20% reducing balance
Fixtures, fittings & equipment
20% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

On 1 October 2015 the group adopted the transitional provisions of FRS 102 with the previous valuations being treated as deemed cost.

CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 14 -
1.8
Fixed asset investments

Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.

 

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.9
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

 

The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.10
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.11
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 15 -
1.12
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 16 -
Basic financial liabilities

Basic financial liabilities, including creditors and loans from fellow group companies are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.13
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.14
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 17 -
1.15
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the group is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.16
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.17
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.18
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Turnover and other revenue
2025
2024
£
£
Turnover analysed by class of business
Sale of specialist lenses
3,417,564
2,425,847
Royalty income
395,328
709,962
3,812,892
3,135,809
Grants received
623
-
Research and development tax credits
34,961
34,271
Recharges made to group undertakings
108,723
201,834
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
3
Turnover and other revenue
(Continued)
- 18 -
2025
2024
£
£
Turnover analysed by geographical market
United Kingdom
2,194,913
1,479,143
Europe
1,050,597
944,419
Rest of the World
567,382
712,247
3,812,892
3,135,809
4
Operating (loss)/profit
2025
2024
£
£
Operating (loss)/profit for the year is stated after charging/(crediting):
Exchange differences apart from those arising on financial instruments measured at fair value through profit or loss
5,394
689
Research and development costs
174,806
171,355
Government grants
(623)
-
Depreciation of owned tangible fixed assets
182,190
181,701
Loss on disposal of tangible fixed assets
910
20,577
Amortisation of intangible assets
181,337
676

 

5
Auditor's remuneration
2025
2024
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the group and company
8,250
7,875
Audit of the financial statements of the company's subsidiaries
28,750
15,750
37,000
23,625
For other services
Taxation compliance services
12,000
9,000
All other non-audit services
7,500
5,305
19,500
14,305
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 19 -
6
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
Direct labour
59
45
-
-
Administration
12
6
6
6
Total
71
51
6
6

Their aggregate remuneration comprised:

Group
Company
2025
2024
2025
2024
£
£
£
£
Wages and salaries
2,123,265
1,662,651
128,979
139,615
Social security costs
254,390
154,222
18,915
13,363
Pension costs
58,233
45,902
5,738
8,827
2,435,888
1,862,775
153,632
161,805
7
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
146,046
141,161
Company pension contributions to defined contribution schemes
6,000
6,000
152,046
147,161

The number of directors for whom retirement benefits are accruing under defined contribution schemes amounted to 1 (2024 - 1).

8
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
153
-
0
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 20 -
9
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
6,642
49,249
Adjustments in respect of foreign tax
3,300
4,286
Total current tax
9,942
53,535
Deferred tax
Origination and reversal of timing differences
(115,318)
32,353
Adjustment in respect of prior periods
2,473
-
0
Total deferred tax
(112,845)
32,353
Total tax (credit)/charge
(102,903)
85,888

The actual (credit)/charge for the year can be reconciled to the expected (credit)/charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
(Loss)/profit before taxation
(685,375)
50,197
Expected tax (credit)/charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
(171,344)
12,549
Tax effect of expenses that are not deductible in determining taxable profit
52,836
1,350
Change in unrecognised deferred tax assets
-
0
62,853
Depreciation on assets not qualifying for tax allowances
4,850
4,850
Other non-reversing timing differences
4,982
-
Deferred tax adjustments in respect of prior years
2,473
-
0
Foreign tax
3,300
4,286
Taxation (credit)/charge
(102,903)
85,888
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 21 -
10
Intangible fixed assets
Group
Goodwill
Development costs
Total
£
£
£
Cost
At 1 January 2025
-
0
81,068
81,068
Additions - separately acquired
-
0
61,314
61,314
Additions - business combinations
2,417,826
-
0
2,417,826
At 31 December 2025
2,417,826
142,382
2,560,208
Amortisation and impairment
At 1 January 2025
-
0
676
676
Amortisation charged for the year
181,337
-
0
181,337
At 31 December 2025
181,337
676
182,013
Carrying amount
At 31 December 2025
2,236,489
141,706
2,378,195
At 31 December 2024
-
0
80,392
80,392
Company
Development costs
£
Cost
At 1 January 2025
81,068
Additions
61,314
At 31 December 2025
142,382
Amortisation and impairment
At 1 January 2025 and 31 December 2025
676
Carrying amount
At 31 December 2025
141,706
At 31 December 2024
80,392
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 22 -
11
Tangible fixed assets
Group
Freehold land and buildings
Plant and machinery
Fixtures, fittings & equipment
Total
£
£
£
£
Cost
At 1 January 2025
1,232,947
1,973,291
758,147
3,964,385
Additions
-
0
18,587
32,333
50,920
Business combinations
80,065
44,464
-
0
124,529
Disposals
-
0
(958)
-
0
(958)
At 31 December 2025
1,313,012
2,035,384
790,480
4,138,876
Depreciation and impairment
At 1 January 2025
380,808
1,113,297
324,156
1,818,261
Depreciation charged in the year
24,460
82,179
75,551
182,190
Eliminated in respect of disposals
-
0
(48)
-
0
(48)
At 31 December 2025
405,268
1,195,428
399,707
2,000,403
Carrying amount
At 31 December 2025
907,744
839,956
390,773
2,138,473
At 31 December 2024
852,139
859,994
433,991
2,146,124
Company
Freehold land and buildings
£
Cost
At 1 January 2025 and 31 December 2025
970,000
Depreciation and impairment
At 1 January 2025
334,678
Depreciation charged in the year
19,400
At 31 December 2025
354,078
Carrying amount
At 31 December 2025
615,922
At 31 December 2024
635,322
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 23 -
12
Fixed asset investments
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Investments in subsidiaries
13
-
0
-
0
3,889,204
50
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 January 2025
50
Additions
1,964,666
Additional shares subscribed
616,688
Transfer on group reorganisation
1,307,800
At 31 December 2025
3,889,204
Carrying amount
At 31 December 2025
3,889,204
At 31 December 2024
50

Further details of the additions in the year are given in note 22.

13
Subsidiaries

Details of the company's subsidiaries at 31 December 2025 are as follows:

Name of undertaking
Country of
Nature of business
Class of
% Held
incorporation
shares held
Direct
Indirect
Ultravision International Limited
England and Wales
Manufacture and supply of contact lenses
Ordinary
100.00
0
Scotlens Limited
England and Wales
Manufacture and supply of contact lenses
Ordinary
100.00
0
Scotlens Holdings Limited
England and Wales
Holding company
Ordinary
100.00
0
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 24 -
14
Stocks
Group
Company
2025
2024
2025
2024
£
£
£
£
Raw materials and consumables
68,882
-
-
-
Finished goods and goods for resale
329,951
549,164
-
0
-
0
398,833
549,164
-
-
15
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
547,077
387,977
42,106
14,984
Corporation tax recoverable
51,232
25,703
28,319
25,703
Amounts owed by group undertakings
25,703
320,221
157,392
2,646,911
Other debtors
4,876
9,155
3,721
9,155
Prepayments and accrued income
191,495
292,635
78,125
128,121
820,383
1,035,691
309,663
2,824,874
Deferred tax asset (note 18)
217,098
87,732
-
0
-
0
1,037,481
1,123,423
309,663
2,824,874
16
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
£
£
£
£
Trade creditors
48,925
89,054
7,286
49,080
Amounts owed to group undertakings
-
0
7,985
1,306,094
-
0
Other taxation and social security
222,979
165,252
107,337
108,384
Other creditors
9,853
32,011
-
0
-
0
Accruals and deferred income
70,797
39,729
14,850
10,783
352,554
334,031
1,435,567
168,247
17
Creditors: amounts falling due after more than one year
Group
Company
2025
2024
2025
2024
£
£
£
£
Other creditors
3,488
-
0
-
0
-
0
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 25 -
18
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

Liabilities
Liabilities
Assets
Assets
2025
2024
2025
2024
Group
£
£
£
£
Accelerated capital allowances
44,534
20,099
(325,421)
(350,556)
Tax losses
-
-
534,824
430,565
Other timing differences
(30)
-
7,695
7,723
44,504
20,099
217,098
87,732
Liabilities
Liabilities
Assets
Assets
2025
2024
2025
2024
Company
£
£
£
£
Accelerated capital allowances
35,428
20,099
-
-
Group
Company
2025
2025
Movements in the year:
£
£
Liability/(Asset) at 1 January 2025
(67,633)
20,099
(Credit)/charge to profit or loss
(112,845)
15,329
Arising on acquisition
7,884
-
Liability/(Asset) at 31 December 2025
(172,594)
35,428

The deferred tax asset set out above relates to carried forward losses which are expected to be utilised in future years. The deferred tax liability set out above is expected to reverse within 48 months and relates to accelerated capital allowances that are expected to mature within the same period.

19
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
58,233
45,902

A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.

CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 26 -
20
Share capital
Group and company
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of 1p each
10,200
10,200
102
102
A ordinary shares of 1p each
867
867
9
9
11,067
11,067
111
111
21
Reserves
Share premium

This reserve records the amount above the nominal value received for shares issued less transaction costs.

Revaluation reserve

This reserve represents the increase in the carrying value of tangible fixed assets to their revalued amount.

Capital redemption reserve

This reserve records the nominal value of shares repurchased by the company.

Capital contribution reserve
This reserve represents a capital contribution made by the ultimate parent company.
Profit and loss reserves

This reserve records the amount of profit after tax retained by the company and not paid out as dividends.

22
Acquisition of a business

On 1 April 2025 the group acquired 100% of the issued capital of Scotlens Holdings Limited and Scotlens Limited (indirect shareholding).

Book Value
Adjustments
Fair Value
Net assets acquired
£
£
£
Property, plant and equipment
124,529
-
124,529
Inventories
60,981
-
60,981
Trade and other receivables
126,394
-
126,394
Cash and cash equivalents
67,971
-
67,971
Trade and other payables
(791,219)
-
(791,219)
Tax liabilities
(33,932)
-
(33,932)
Deferred tax
(7,884)
-
(7,884)
Total identifiable net assets
(453,160)
-
(453,160)
Goodwill
2,417,826
Total consideration including costs
1,964,666
CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
22
Acquisition of a business
(Continued)
- 27 -
The consideration was satisfied by:
£
Cash
1,964,666
Contribution by the acquired business for the reporting period included in the group statement of comprehensive income since acquisition:
£
Turnover
779,367
Profit after tax
119,496

The goodwill arising on the acquisition of the business is attributable to the anticipated profitability of the distribution of the company's products and the future operating synergies from the combination.

 

Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

After the completion of the acquisition the company subscribed for 69 new ordinary shares of £1 each in Scotlens Holdings Limited for a consideration of £616,688.

 

Subsequently, ownership of Scotlens Limited was transferred from Scotlens Holdings Limited to the company as part of a group reorganisation.

23
Related party transactions
Transactions with related parties

During the year the group entered into the following transactions with related parties:

Purchases of services
2025
2024
£
£
Group
Services provided by an entity with a common director
12,000
-

As a wholly owned subsidiary of Seed Co. Ltd, the company is exempt from the requirements of FRS 102 (S.33.1A) to disclose transactions with other wholly owned members of the group headed by Seed Co. Ltd as consolidated financial statements are publicly available.

24
Controlling party

The company is controlled by Seed Co. Ltd by virtue of their majority shareholding.

The company's ultimate parent undertaking is Seed Co. Ltd, a company registered on the Tokyo Stock Exchange.

CONTACT LENS PRECISION LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 28 -
25
Cash absorbed by group operations
2025
2024
£
£
Loss after taxation
(582,472)
(35,691)
Adjustments for:
Taxation (credited)/charged
(102,903)
85,888
Investment income
(153)
-
0
Loss on disposal of tangible fixed assets
910
20,577
Amortisation and impairment of intangible assets
181,337
676
Depreciation and impairment of tangible fixed assets
182,190
181,701
R&D tax credit
(34,961)
-
Movements in working capital:
Decrease/(increase) in stocks
211,312
(164,381)
Decrease/(increase) in debtors
367,231
(378,607)
(Decrease)/increase in creditors
(769,208)
182,998
Cash absorbed by operations
(546,717)
(106,839)
26
Analysis of changes in net funds - group
1 January 2025
Cash flows
31 December 2025
£
£
£
Cash at bank and in hand
924,050
(189,935)
734,115
2025-12-312025-01-01falsefalseCCH SoftwareCCH Accounts Production 2026.100S CrossN ShinjoT SugiyamaM UrakabeS KubotaM KumasakaT SatoT KinoshitaS Crossfalse00920009bus:Consolidated2025-01-012025-12-31009200092025-01-012025-12-3100920009bus:Director12025-01-012025-12-3100920009bus:Director22025-01-012025-12-3100920009bus:Director32025-01-012025-12-3100920009bus:Director72025-01-012025-12-3100920009bus:Director82025-01-012025-12-3100920009bus:CompanySecretary12025-01-012025-12-3100920009bus:Director42025-01-012025-12-3100920009bus:Director52025-01-012025-12-3100920009bus:Director62025-01-012025-12-3100920009bus:RegisteredOffice2025-01-012025-12-3100920009bus:Consolidated2025-12-31009200092025-12-3100920009bus:Consolidated2024-01-012024-12-31009200092024-01-012024-12-3100920009core:Goodwillbus:Consolidated2025-12-3100920009core:Goodwillbus:Consolidated2024-12-3100920009core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2025-12-3100920009core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2024-12-3100920009bus:Consolidated2024-12-3100920009core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2025-12-3100920009core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2024-12-3100920009core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-12-3100920009core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-31009200092024-12-3100920009core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2025-12-3100920009core:PlantMachinerybus:Consolidated2025-12-3100920009core:FurnitureFittingsbus:Consolidated2025-12-3100920009core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-12-3100920009core:PlantMachinerybus:Consolidated2024-12-3100920009core:FurnitureFittingsbus:Consolidated2024-12-3100920009core:LandBuildingscore:OwnedOrFreeholdAssets2025-12-3100920009core:LandBuildingscore:OwnedOrFreeholdAssets2024-12-3100920009core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2025-12-3100920009core:CurrentFinancialInstrumentsbus:Consolidated2024-12-3100920009core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-12-3100920009core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3100920009core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3100920009core:ShareCapitalbus:Consolidated2025-12-3100920009core:ShareCapitalbus:Consolidated2024-12-3100920009core:SharePremiumbus:Consolidated2025-12-3100920009core:SharePremiumbus:Consolidated2024-12-3100920009core:RevaluationReservebus:Consolidated2025-12-3100920009core:RevaluationReservebus:Consolidated2024-12-3100920009core:CapitalRedemptionReservebus:Consolidated2025-12-3100920009core:CapitalRedemptionReservebus:Consolidated2024-12-3100920009core:OtherMiscellaneousReservebus:Consolidated2025-12-3100920009core:OtherMiscellaneousReservebus:Consolidated2024-12-3100920009core:RetainedEarningsAccumulatedLossesbus:Consolidated2025-12-3100920009core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-12-3100920009core:ShareCapital2025-12-3100920009core:ShareCapital2024-12-3100920009core:SharePremium2025-12-3100920009core:SharePremium2024-12-3100920009core:RevaluationReserve2025-12-3100920009core:RevaluationReserve2024-12-3100920009core:CapitalRedemptionReserve2025-12-3100920009core:CapitalRedemptionReserve2024-12-3100920009core:OtherMiscellaneousReserve2025-12-3100920009core:OtherMiscellaneousReserve2024-12-3100920009core:RetainedEarningsAccumulatedLosses2025-12-3100920009core:RetainedEarningsAccumulatedLosses2024-12-3100920009core:ShareCapitalbus:Consolidated2023-12-3100920009core:SharePremiumbus:Consolidated2023-12-3100920009core:CapitalRedemptionReservebus:Consolidated2023-12-31009200092023-12-3100920009core:ShareCapital2023-12-3100920009core:SharePremium2023-12-3100920009core:RevaluationReserve2023-12-3100920009core:CapitalRedemptionReserve2023-12-3100920009core:RetainedEarningsAccumulatedLosses2023-12-3100920009bus:Consolidated2023-12-3100920009core:Goodwill2025-01-012025-12-3100920009core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3100920009core:LandBuildingscore:OwnedOrFreeholdAssets2025-01-012025-12-3100920009core:PlantMachinery2025-01-012025-12-3100920009core:FurnitureFittings2025-01-012025-12-3100920009core:UKTaxbus:Consolidated2025-01-012025-12-3100920009core:UKTaxbus:Consolidated2024-01-012024-12-3100920009core:ForeignTaxbus:Consolidated2025-01-012025-12-3100920009core:ForeignTaxbus:Consolidated2024-01-012024-12-3100920009bus:Consolidated12025-01-012025-12-3100920009bus:Consolidated12024-01-012024-12-3100920009core:Goodwillbus:Consolidated2024-12-3100920009core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2024-12-3100920009bus:Consolidated2024-12-3100920009core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-3100920009core:Goodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2025-01-012025-12-3100920009core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2025-01-012025-12-3100920009core:ExternallyAcquiredIntangibleAssetsbus:Consolidated2025-01-012025-12-3100920009core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:ExternallyAcquiredIntangibleAssets2025-01-012025-12-3100920009core:Goodwillbus:Consolidated2025-01-012025-12-3100920009core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2025-01-012025-12-3100920009core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-12-3100920009core:PlantMachinerybus:Consolidated2024-12-3100920009core:FurnitureFittingsbus:Consolidated2024-12-3100920009core:LandBuildingscore:OwnedOrFreeholdAssets2024-12-3100920009core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2025-01-012025-12-3100920009core:PlantMachinerybus:Consolidated2025-01-012025-12-3100920009core:FurnitureFittingsbus:Consolidated2025-01-012025-12-3100920009core:Subsidiary12025-01-012025-12-3100920009core:Subsidiary22025-01-012025-12-3100920009core:Subsidiary32025-01-012025-12-3100920009core:Subsidiary112025-01-012025-12-3100920009core:Subsidiary222025-01-012025-12-3100920009core:Subsidiary332025-01-012025-12-3100920009core:CurrentFinancialInstrumentsbus:Consolidated2025-12-3100920009core:CurrentFinancialInstruments2025-12-3100920009core:CurrentFinancialInstruments2024-12-3100920009core:CurrentFinancialInstrumentsbus:Consolidated12025-12-3100920009core:CurrentFinancialInstrumentsbus:Consolidated12024-12-3100920009core:CurrentFinancialInstruments22025-12-3100920009core:CurrentFinancialInstruments22024-12-3100920009core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated12025-12-3100920009core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated12024-12-3100920009core:Non-currentFinancialInstrumentscore:AfterOneYear22025-12-3100920009core:Non-currentFinancialInstrumentscore:AfterOneYear22024-12-3100920009bus:PrivateLimitedCompanyLtd2025-01-012025-12-3100920009bus:FRS1022025-01-012025-12-3100920009bus:Audited2025-01-012025-12-3100920009bus:ConsolidatedGroupCompanyAccounts2025-01-012025-12-3100920009bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP